The study, titled ‘Managing the mental state’ to tackle anxiety-related freezing of gait in people with Parkinson’s disease, set out to test a proposition that is increasingly supported by neuroscience but has rarely been evaluated in such a direct, trial-based fashion: that freezing of gait is not purely a motor problem, and that interventions aimed at the emotional and cognitive machinery of the brain may therefore yield measurable benefits for walking. The researchers framed their approach around the observation that anxiety and freezing tend to travel together, with anxious arousal narrowing attention, disrupting the automatic flow of movement and making episodes more likely at precisely the moments when people with Parkinson’s can least afford them.

Freezing of gait affects a substantial proportion of people with Parkinson’s as the disease progresses, and its mechanisms remain only partially understood. Contemporary models describe it as arising from a breakdown in the neural circuits that normally allow walking to proceed on autopilot. In healthy individuals, gait is largely controlled by subcortical loops that require little conscious attention. Parkinson’s disease damages these loops, forcing patients to rely more heavily on deliberate, effortful control of stepping. That compensation works reasonably well in calm, open environments, but it collapses under pressure. When cognitive resources are consumed by worry, when a doorway or a crowd demands rapid navigation, or when the fear of freezing itself takes hold, the fragile control system is overwhelmed and the gait pattern fragments into the characteristic stuttering, shuffling or complete arrest that patients know so well.

Anxiety enters this picture at several levels. There is the situational anxiety of approaching a feared trigger, such as turning in a tight space or crossing a busy road. There is the anticipatory anxiety that builds as people begin to organize their lives around avoiding situations in which freezing might occur, a pattern that can shrink confidence and mobility over time. And there is the physiological arousal that accompanies anxious states — elevated heart rate, muscle tension and heightened vigilance — all of which alter the way the brain allocates attention to movement. Researchers have argued that this arousal effectively competes with the already-strained motor control resources of the Parkinsonian brain, lowering the threshold at which freezing is triggered.

If anxiety is a genuine driver of freezing rather than a mere byproduct, the reasoning goes, then teaching patients to manage that anxiety should reduce the frequency or severity of episodes. This is the hypothesis the randomized controlled trial was designed to test. Rather than focusing on the mechanics of stepping, as many gait rehabilitation programs do, the intervention centered on strategies for regulating the mental state: recognizing the early signs of anxious arousal, applying techniques to calm and refocus attention, and reframing the fear of freezing that can itself precipitate an episode. Participants were randomly assigned to receive the mental-state intervention or a comparison condition, allowing the researchers to separate the specific effects of the anxiety-focused approach from the general benefits of attention, practice and clinical contact.

The randomized design matters. Freezing of gait fluctuates naturally from day to day and responds strongly to context, expectation and environment, which makes uncontrolled observations notoriously unreliable. A patient who believes a therapy will help may walk more confidently, freeze less and attribute the change to the treatment, regardless of the treatment’s specific content. By randomly allocating participants and including a comparator, the trial aimed to isolate the true effect of managing the mental state from placebo responses, regression to the mean and the natural course of the disease. Such rigor is essential if anxiety-focused approaches are to earn a place alongside medication, deep brain stimulation and cueing strategies in the standard toolkit for gait problems in Parkinson’s.

The broader significance of the trial lies in what it says about the nature of Parkinson’s disease itself. For much of the twentieth century, Parkinson’s was understood primarily as a disorder of movement, defined by tremor, rigidity, slowness and postural instability. Research over recent decades has progressively widened that picture, revealing profound non-motor dimensions — sleep disturbance, loss of smell, cognitive change, depression and anxiety — that often precede the motor symptoms by years and shape quality of life at least as much. The recognition that anxiety is not simply an understandable reaction to a difficult diagnosis but a modifiable factor with a direct bearing on motor function represents a meaningful shift. It reframes the psychological life of the patient as part of the disease mechanism, and therefore as a legitimate target of treatment.

The trial also speaks to a practical reality of clinical care. Pharmacological options for freezing of gait are limited; dopaminergic medications help some patients some of the time, but freezing frequently persists or even worsens as the disease advances, and no drug is approved specifically for the symptom. Physiotherapy and cueing techniques — rhythmic auditory signals, visual targets on the floor, laser attachments to walking frames — offer genuine benefit by providing external rhythm and attentional anchors, yet they do not address the internal state that can override them. An approach that equips patients to regulate anxiety in the moment could, in principle, be combined with these existing strategies, giving people a layered set of defenses: environmental cues for the feet, mental strategies for the mind.

For patients and families, the message embedded in this research is one of agency. Freezing of gait can feel arbitrary and humiliating, an unpredictable betrayal by one’s own body. The idea that the mental state — the breath, the attention, the fearful anticipation — is not just a victim of freezing but a participant in it offers a handle on the problem. It suggests that the moments before an episode, when the heart begins to race and the mind fills with dread, are not merely a prelude but an intervention point. Learning to notice that moment, and to act on it, may be as therapeutically important as any exercise performed in a clinic.

Much remains to be established. The mechanisms linking anxiety to freezing are still being mapped, the durability of mental-state interventions over months and years is an open question, and the optimal way to integrate such training with medication and physical therapy has yet to be defined. But the trial marks a clear step in a direction that many in the field consider overdue: treating the person with Parkinson’s as an integrated system in which emotion, cognition and movement are inseparable. If managing the mental state proves to loosen the grip of freezing, it will validate a simple but powerful idea — that in Parkinson’s disease, the mind is not a bystander to the gait, but part of the machinery that keeps it moving.

Subject of Research: A randomized controlled trial of mental-state management to reduce anxiety-related freezing of gait in Parkinson's disease.

Article Title: ‘Managing the mental state’ to tackle anxiety-related freezing of gait in people with Parkinson’s disease: a randomized controlled trial

Article References: Vissers, G., Tosserams, A., Duits, A. A., Helmich, R. C., Bloem, B. R., Young, W. R., & Nonnekes, J. (2026). ‘Managing the mental state’ to tackle anxiety-related freezing of gait in people with Parkinson’s disease: a randomized controlled trial. npj Parkinson's Disease. https://doi.org/10.1038/s41531-026-01571-w

Image Credits: AI Generated

DOI: 10.1038/s41531-026-01571-w

Keywords: Parkinson's disease, freezing of gait, anxiety, randomized controlled trial, gait rehabilitation, motor symptoms, mental state, npj Parkinson's Disease, neurodegeneration, clinical trial, movement disorders, anxiety management

This distinction is known in rehabilitation science as the gap between capacity and performance. Capacity describes the upper level of function a person can demonstrate during a structured test, such as walking a measured distance, rising from a chair or maintaining balance while following instructions. Performance refers to mobility as it unfolds in real environments, where distractions, fatigue, anxiety, time pressure, uneven surfaces and social demands all compete for attention. Someone with Parkinson’s disease may therefore complete a laboratory walking test reasonably well while taking far fewer steps, moving more slowly or avoiding challenging routes during daily life. The study addresses these measures as related but not interchangeable windows into mobility.

The difference matters because Parkinson’s disease is not a single-symptom disorder. Its motor features arise largely from disturbances in neural circuits involved in movement selection, scaling and automatic control. Reduced amplitude of movement can shorten steps, bradykinesia can slow transitions and rigidity can restrict the fluid rotation of the trunk and limbs. Postural instability may make turning or negotiating stairs more difficult, while freezing of gait can interrupt walking suddenly, especially in narrow spaces or when a person tries to change direction. These problems may appear in a clinical examination, but their effect can vary sharply depending on the task and the surrounding environment.

Non-motor symptoms add another layer of complexity. Sleep disruption can reduce alertness and physical reserve; depression or apathy can lower motivation to leave home; anxiety may intensify hesitation in situations where falling feels possible. Cognitive changes can make it harder to divide attention between walking and another task, such as carrying a conversation, reading signs or navigating an unfamiliar building. Autonomic symptoms, including blood-pressure instability, may produce dizziness or weakness, while pain and fatigue can make movement feel costly even when basic muscle power remains relatively preserved. By examining motor and non-motor influences together, the research highlights mobility as a whole-person outcome rather than a simple readout of gait speed.

A central technical issue is that different mobility tests measure different physiological systems. A short walk may be sensitive to bradykinesia and stride regulation, whereas repeated chair rises place greater demands on leg force, postural transitions and coordination. Balance tasks probe the integration of visual, vestibular and somatosensory information. Longer walking assessments bring endurance and fatigue into view, while dual-task tests—walking while counting, talking or responding to cues—challenge executive control and attention. Wearable sensors can extend this assessment beyond the clinic by recording step counts, walking bouts, turning patterns and periods of inactivity over several days. Each method captures a particular domain, and the study’s premise is that no single measure can represent the entire mobility experience.

This framework also helps explain why two people with similar scores on a conventional neurological examination may have very different levels of independence. One individual might retain adequate walking capacity but rarely venture outdoors because of fear of falling. Another might walk frequently but experience subtle instability, frequent pauses or exhausting effort that is not captured by a brief test. In this context, performance is not merely a weaker version of capacity. It is the product of physical ability interacting with confidence, cognition, environment, habits and opportunity. The paper’s emphasis on separate mobility domains encourages researchers and clinicians to ask not only, “Can the patient perform this movement?” but also, “How is movement being used in daily life?”

The implications extend to treatment. Medication that improves rigidity or slowness may raise performance on a clinic-based test, but it may not automatically restore community mobility if anxiety, fatigue or executive dysfunction continues to limit activity. Conversely, a person whose basic motor capacity changes little could still become more active through targeted balance training, cueing strategies, occupational therapy, home modifications or interventions addressing sleep and mood. A precise assessment can therefore help match treatment to the mechanism limiting mobility. If the main barrier is step initiation, cueing and gait-focused rehabilitation may be appropriate; if the barrier is divided attention, cognitive-motor training and environmental strategies may be more relevant.

The research is also important for the design of clinical trials. A therapy can appear ineffective if investigators measure only one outcome that does not reflect the symptom it is designed to change. Likewise, an improvement in capacity may be mistaken for a meaningful improvement in independence if real-world performance is never monitored. Combining standardized tests with patient-reported outcomes and passive wearable measurements could provide a more complete picture. Such an approach may reveal whether an intervention changes walking speed, reduces inactivity, increases the number of daily walking bouts or enables people to participate in activities they previously avoided. These distinctions are increasingly valuable as Parkinson’s research moves toward personalized treatment and digital health monitoring.

For patients and families, the capacity-performance model offers a language for describing experiences that can otherwise be difficult to communicate. A person may say, “I can walk, but I cannot walk safely in the supermarket,” or, “I can manage stairs in the morning, but not after a tiring day.” Those statements are not contradictory; they describe different demands placed on the nervous system. Recognizing that gap can prevent underestimating disability when a clinic demonstration looks reassuring, while also avoiding an overly narrow focus on impairment. It places everyday participation—shopping, visiting friends, working, exercising and moving confidently at home—alongside conventional neurological measurements.

The work by Bianchini, Petit, Rinaldi and colleagues ultimately presents mobility in Parkinson’s disease as a multidimensional, context-dependent phenomenon. Motor symptoms remain fundamental, but they operate within a network that includes attention, mood, sleep, autonomic function, fatigue and the physical and social environment. By separating capacity-related and performance-related measures, the study provides a more refined way to interpret what mobility tests can—and cannot—tell us. The broader message is likely to resonate well beyond Parkinson’s clinics: meaningful recovery is not simply the ability to complete a movement when asked. It is the ability to use that movement safely, repeatedly and confidently in the unpredictable world where daily life takes place.

Subject of Research: Motor and non-motor symptoms and their effects on capacity- and performance-related mobility measures in Parkinson’s disease

Article Title: Motor and non-motor symptoms impact on different domains of capacity- and performance-related mobility measures in Parkinson’s disease

Article References: Bianchini, E., Petit, P., Rinaldi, D. et al. Motor and non-motor symptoms impact on different domains of capacity- and performance-related mobility measures in Parkinson’s disease. npj Parkinson’s Disease (2026). https://doi.org/10.1038/s41531-026-01522-5

Image Credits: AI Generated

DOI: 10.1038/s41531-026-01522-5

Keywords: Parkinson’s disease, mobility, gait, motor symptoms, non-motor symptoms, capacity, performance, balance, bradykinesia, wearable sensors, rehabilitation, daily living